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Introduction:  Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate that affects
ageing men. As the number of men affected by this condition will only continue to grow with the aging
population, finding new strategies and new therapeutic options for its treatment is crucial. Androgenic
hormones have been known to play an important role in the development of BPH and they have been a
target in its medical treatment. Estrogens have also been implicated in BPH but in contrast to androgens,
the functions of estrogens in the prostate are still obscure.
Objective:  This review aims to highlight the roles of estrogen in the development of BPH.
Methods:  Authors reviewed the literature covering the past forty years to highlight the roles of estrogen in
the prostate and BPH. Data from authors’ experimental work in this field was also referenced.
Results: The effects of estrogen in the prostate are mediated by estrogen receptors alpha and beta (ER
and ER). These two receptors have different expression and functions in the prostate, thereby presenting a
window of opportunity to selectively target them for therapeutic purposes in BPH. The actions of estrogens,
as mediated by estrogen receptors, appear to contribute to the development of BPH in men through an
intricate molecular process that is yet to be fully elucidated. Although surgery remains the gold standard in
the treatment of BPH, understanding the elusive role of estrogen in BPH, in addition to the established role
of androgens, would enhance the current therapeutic options and perhaps lead to the development of new
s that phytoestrogens might be beneficial in the management of BPH.therapies. There are indication∗ Corresponding author.
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Conclusion:  This review highlights the roles of estrogen as well as the therapeutic use of phytoestrogens
in the prevention and management of BPH.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open
























































































enign prostatic hyperplasia (BPH), also referred to as benign pro-
tatic hypertrophy, is a non-malignant enlargement of the prostate
land affecting aging men [1]. BPH is the most common condition
ffecting men and is present in 50% of men aged above 60 years of
ge, while over 80% of men above 80 years show histological evi-
ence of BPH, [2–4], the incidence and symptom severity of which
s known to be affected by race and ethnicity [5].
he prostate is an accessory reproductive organ in the male that
unctions in sperm transport and nourishment. Although there is
 considerable diversity in morphology across species, the human
rostate, which is a sex hormone dependent organ, is ovoid shaped
nd located at the neck of the bladder. The human prostate con-
ists of both glandular and fibromuscular tissues and is made
p of three histological zones which are central, peripheral and
ransition zones with clinically significant BPH occurring mainly
n the transition zone of the prostate [6,7]. The transition zone,
hich is located in the periurethral area of the prostate gland,
ccounts for approximately 5% of total prostate volume although
he factor responsible for proliferation within this zone is currently
nknown [7].
PH is characterized by stroma and epithelia hyperplasia of the
rostate gland, especially at the transition zone, and can cause nar-
owing of the urethra as it passes through the prostate causing
ladder outlet obstruction. BPH and bladder outlet obstruction cause
 cluster of urinary difficulties ranging from storage to voiding such
s nucturia and increased urinary frequency [8–10]. These urinary
oiding problems are generally referred to as lower urinary tract
ymptoms (LUTS) [10]. LUTS significantly affects quality of life
s a significant number of men reaching 80 years are said to require
urgical intervention [11].
ndrogenic hormones have been known to play an important role in
he development of BPH [9] and they have been a target in its medical
reatment. However, androgens might not be the only significant
ormone in BPH since estrogen is also a metabolite of testosterone.
onsequently, the induction of BPH that is attributed to androgens
ight also be due to estrogens. This review highlights the roles of
strogen in the prostate as well as the potential therapeutic use of
hytoestrogens in the management of BPH.
tiology  of  BPHany theories have been postulated to explain how BPH develops.
his includes embryonic reawakening, androgens, estrogens, aging
nd inflammation [12,13]. Although aging and hormonal alterations





f BPH [9], data has also shown prostate growth rate to be higher
n BPH patients with metabolic conditions such as insulin resis-
ance syndrome, abdominal obesity, hypertension, hyperglycemia
nd reduced level of high density lipoprotein [14]. Age has been
roved to play a role in the progressive development of pathologic
nd clinical BPH as virtually all men present with histological BPH
s they grow [1,11]. However, the precise etiology of BPH has not
een absolutely unraveled.
athological BPH develops when there is hyperplasia in epithelia
nd stromal growth that coalesces into microscopic and macroscopic
odules in the prostate gland. It is a phase in the development of
enign prostate hypertrophy that involves the microscopic stage
hich in turn leads to the macroscopic stage and neither of these
roduces symptomatic clinical dysuria. Although all men will
ventually develop microscopic stage of BPH with advancement
n age, only about half of the men having microscopic benign
rostatic hyperplasia are likely to develop macroscopic enlarge-
ent of the prostate gland. It is possible though that all the
PH nodules might possibly be initiated by different molecu-
ar mechanisms giving room for multiple theories to explain the
istinct types of BPH. A hormonal theory involving dysregula-
ion of stroma-epithelial interaction is believed to be responsible
or BPH development although the pathogenesis is not yet
bsolutely clear [9].
ndrogenic  hormones
ndrogenic hormones include testosterone, dihydrotestosterone
DHT), dehydroepiandrosterone (DHEA), androstenedione and
-androstenedione. Androgens are synthesized from cholesterol.
estosterone is the main circulating androgen in men and it’s impor-
ant for the development of accessory sex organs and secondary
exual characteristics. About 90% of testosterone production is by
he testes while the rest comes from the adrenal glands. Circulat-
ng testosterone is mostly bound to sex hormone binding globulin
SHGB). DHT, the most potent androgen in men, is metabolized
rom testosterone through the activity of 5-reductase enzyme. DHT
lays a crucial role in the differentiation and growth of the prostate
land during fetal development as well as in the development of
ale external genitalia and secondary sexual characteristics [15].
n the prostate, testosterone is converted to DHT by the membrane
ound NADPH-dependent enzyme, type II 5-reductase. Although
he pathogenesis of BPH is not completely understood, the presence
f androgens appears to be permissive in the development of BPH
9]. Inhibition of the production or actions of DHT can result in
he inhibition of the growth of the prostate gland. There is substan-
ial clinical evidence that androgen and DHT play a key role in the
























































The role of estrogen in the development of benign prostatic hyperpl
Estrogen  and  their  roles  in  BPH
Androgens might not be the only significant hormone in the develop-
ment of BPH since estrogens, some of which could be synthesized
from testosterone, can also influence normal prostate gland func-
tions and may well potentiate pathological growth [18]. Estrogens
within circulation can either be endogenous or exogenous. Endoge-
nous estrogens are mostly produced by the gonads and they include:
estrogen (E1), estradiol-17 (E2) and estriol (E3). Estrogen (E1)
is produced from testosterone through the activity of aromatase
enzyme although it is a weak estrogen with minimal influence on
estrogenic pathways within the prostate. Estradiol-17 is formed
from aromatization of testosterone mainly in fat and muscles while
up to 20% is produced from the Leydig cells in the testis. Such local
production of estradiol-17 has been implicated in BPH [19].
Estrogen plays an important role during prostate development and
studies have shown that excessive estrogenization during prostatic
development may contribute to the high incidence of BPH cur-
rently observed in the aging male population. Neonatal exposure to
estrogen interrupts normal prostate development. Serum and intra-
prostatic estradiol levels tend to increase in men with age despite
decreasing levels of estrogen and testosterone and patients with
larger volumes of BPH tend to have high levels of serum estradiol
[20–23]. Adipose tissues express aromatase enzyme, which converts
testosterone to estrogen. Adiposity tends to increase with aging.
Conversely, testosterone production by the testes tends to decrease
with aging. Thus, aging results in a significant increase in the relative
level of estrogen compared to testosterone. The estrogen-dominant
status in men after middle age may therefore be the most significant
factor in the induction and progression of BPH [20]. In addition,
estrogen action in the prostate may be independent of serum levels
of estrogen since estrogen is produced locally within the prostate
via conversion of testosterone to 17-estradiol by aromatase enzyme
expressed within the prostate stroma [24].
Estrogen effects on the prostate gland may also be indirectly
mediated through alterations in other serum hormones. Estrogens
stimulate the pituitary release of prolactin and prolactin induces
prostate enlargement and decreased apoptosis [25]. Also, estradiol
inhibits luteinizing hormone secretion and production of androgens
by the testis. Besides these indirect effects, many of the estro-
genic effects on the prostate are directly mediated through prostatic
expression of estrogen receptors [26,27].
Estrogen  receptors
Estrogen receptors (ERs) are members of the steroid hormone
nuclear receptor superfamily found ubiquitously throughout the ani-
mal kingdom. These ligand-activated transcription factors mediate
the actions of estrogens and are classified as estrogen receptor alpha
(ER) and estrogens receptor beta (ER) [28]. The human ER
gene, located on chromosome 6, encodes 595 amino acids with
a molecular weight of 66 kDa while ER  gene, located on chro-
mosome 14, encodes 530 amino acids with a molecular weight of
54 kDa. ERs are composed of 6 functional modules; an N-terminal
(NTD) also called A/B domain, a DNA-binding (C) domain, a hinge






he A/B domain of ERs accommodates the AF-1 (activation
unction-1) domain and specifies the cell and promoter-specific
ctivity of the receptor as well as co-receptor protein interactions.
he A/B domain accounts for the greatest structural disparity with
nly about 30% homology between the two ERs while ER  is
bout 90 nucleotides longer than ER. The C domain functions in
he recognition and binding of the receptors to cis-acting enhancer
NA sequences or estrogen response elements (ERE) located
ithin regulatory regions of target genes. The C domain is the most
ighly conserved region with about 95% homology between the two
Rs hence, the similarity in affinity for the same EREs by ER  and
R. The D domain, with about 30% homology, harbors a nuclear
ocalization signal that influences cellular compartmentalization of
he receptor. The E domain is a highly structured, multifunctional
egion that serves to specifically bind estrogens and provide for
igand-dependent transcriptional activity. Also harbored within the
 domain is a strong receptor dimerization interface with about
0% homology in the primary sequence of the E region of two ERs.
he F domain, which has about 20% homology, encodes the AF-2
activation function-2) domain and functions in receptor stability
nd co-activator recruitment [28–31].
R  is localized in the prostate stroma while ER  is present in both
pithelia and stroma [32]. These receptors bind endogenous estro-
ens in prostate tissue and regulate prostate gene expression. ER
romotes inflammation and hyperplasia while ER  serves to exert
ntiproliferative and proapoptotic effect in the prostate [33]. Due to
he difference in the homology between ER  and ER, their bind-
ng affinities for certain ligands also differ. This results in a situation
here some estrogen receptor ligands selectively modulate estro-
en action in the prostate. This class of compounds is collectively
eferred to as selective estrogen modulators (SERMs). Phytoestro-
ens have also been observed to selectively target ERs [34].
hytoestrogens
he demand for complementary and alternative therapies, includ-
ng an interest in the use of phytotherapy has increased in recent
imes [35]. This is especially important as some of the medica-
ions currently in use for the treatment of BPH have undesirable
dverse effects [36,37]. Phytoestrogens, which are naturally occur-
ing compounds from plants that mimic estrogens, have been known
o be used in the treatment and prevention of BPH. The major
lasses of phytoestrogens include isoflavones, lignans and coumes-
ans [35,38–40]. Isoflavones are perhaps the most researched class
f phytoestrogens. They are polyphenolic compounds which are nat-
rally found conjugated to sugar molecules as biologically inactive
lycosides. Upon the breakdown of isoflavone glycoside conjugates,
he sugar molecules are released resulting in biologically active
soflavone aglycones such as genistein, daidzein, and glycitein.
soflavones are most abundant in legumes like soybeans, as well
s in grains, nuts wine and berries [41]. Lignans are constituents of
lant cell walls and found in many fiber-rich foods and fruits such
s wheat, barley, rice, linseed, cherries, apples, pears and garlic
35,40,42]. Coumestans are phenolic phytoestrogens with coumes-
erol being the major constituent of this group. Coumestans are
nown for a variety of biological activities and they can be found in
lfalfa, clover and the sprout of beans [40].
he consumption of plants such as soy, red clover, African plum




































































larly in ameliorating the symptoms of BPH is well documented
43–46]. Several experimental animal studies have shown the ben-
fits of phytoestrogen in the treatment of BPH [18,34,47–50]. For
xample, the ethanolic extract of Echinops  echinatus  was shown
o confer considerable improvement on the prostatic histoarchitec-
ure of testosterone-induced prostatic hyperplasia in rats [2]. Also,
he aqueous extract of bitter leaf (Vernonia  amygdalina) has been
hown to ameliorate testosterone-induced BPH in an experimental
nimal model [50,51]. Red maca (Lepidium  meyenii), a crucifer-
us plant from the highland of Peru, was likewise shown to have
educed the ventral prostate size in normal and testosterone-treated
ats [47]. The possible mechanisms of action of phytoestrogens may
e related to their structural similarity to estrogens and their abil-
ty to act as weak agonist or antagonists of estrogen. They could
lso act as anti-androgens by competing for androgen receptors and
y regulating the activity of 17-hydroxysteroid dehydrogenase, an
nzyme that is involved in the metabolism of testosterone [35].
linical management of BPH with saw palmetto is very popular
52–55]. Though saw palmetto extract has been shown to be ben-
ficial in the treatment of LUTS that is associated BPH [56], the
utcome of clinical trials has not convincingly proved its efficacy
ompared with placebo [57]. Perhaps this is due to different formu-
ations of saw palmetto extract used in these studies and inherent
aws in the research designs of some of the studies. Hence, it would
e necessary to conduct vigorous research and clinical trials to prove
he effectiveness or otherwise of saw palmetto extract in the treat-
ent of BPH. Meanwhile, the current status of saw palmetto extract
n the treatment of BPH is that it is safe and could be effective, par-
icularly in improving nocturia and other self-reported symptoms
58].
onclusion
PH is a non-malignant enlargement of the prostate that affects a
ignificant population of men above 50 years with substantial effect
n quality of life. The actions of estrogens, as mediated by estrogen
eceptors, appear to contribute to the development of BPH in men
hrough an intricate molecular process that is yet to be fully eluci-
ated. Although surgery remains the gold standard in the treatment
f BPH, understanding the elusive role of estrogen in BPH, in addi-
ion to the established role of androgens, would enhance the current
herapeutic options and perhaps lead to the development of new ther-
pies. Therapeutic use of phytoestrogens could be further explored
o better harness phytoestrogens in the prevention and management
f BPH.
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